Last reviewed · How we verify
Foradil Aerolizer, High Dose
beta2-adrenergic receptor agonist
beta2-adrenergic receptor agonist Used for Asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Foradil Aerolizer, High Dose |
|---|---|
| Also known as | Formoterol |
| Sponsor | AstraZeneca |
| Drug class | Long-acting beta2-adrenergic receptor agonist (LABA) |
| Target | beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Foradil Aerolizer, a high-dose formulation of formoterol, is a long-acting beta2-adrenergic receptor agonist (LABA) used in the maintenance and control of asthma symptoms and to prevent bronchospasm in patients with chronic obstructive pulmonary disease (COPD).
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Cough
- Dysphonia
- Headache
- Nausea
- Tachycardia
Key clinical trials
- Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED) (PHASE3)
- Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED) (PHASE3)
- Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma (PHASE2)
- Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I (PHASE3)
- Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II (PHASE3)
- A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |